MARKET OUTLOOK


With a drug-treated population of more than 4 million people in the United States and EU5, the psoriasis market has been a lucrative space for drug developers,resulting in a plethora of approved agents with diverse mechanisms of action to treat the disease. In recent years, the dynamics of the psoriasis market have started to change; there has been a shift from the use of established TNF-α inhibitors as earlier-line agents to the earlier use of biologics like Stelara. More recently, the approval ofIL-17 inhibitorssuch as Cosentyx and Taltz and IL-23 inhibitors such as Tremfya has resulted in increased pressure on these conventional agents for psoriasis. Nonetheless, the moderate to severe psoriasis early- and late-phase pipeline has several promising agents because drug developers realize that, despite multiple current treatments, an unmet need remains for novel agents that can differentiate themselveson the attributes of efficacy, delivery convenience, and catering to a broad patient population.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for moderate to severe psoriasis?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?
  • What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new moderate to severe psoriasis drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European dermatologists fielded in January 2019.

Key companies:  AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis.

Key drugs: Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz, Tremfya.

Table of contents

  • Detailed, Expanded Analysis (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Moderate to Severe Psoriasis
      • Key Findings: Unmet Need in Moderate to Severe Psoriasis and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Moderate to Severe Psoriasis Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent Offering Improved Sustained Efficacy in Moderate to Severe Psoriasis
        • Opportunity: A Novel Agent Offering Efficacy in a Broad Patient Population
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Moderate to Severe Psoriasis Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Mohit Nasa, MBA

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis. He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.


Related Reports

Psoriasis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Palmoplantar Pustular Psoriasis/Generalized Pustular Psoriasis (US )

MARKET OUTLOOK Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP])...

View Details

Psoriasis | Access and Reimbursement | US | 2018

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (

View Details

Psoriasis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbr...

View Details

Psoriasis | Emerging Therapies | Skyrizi Launch Tracking Wave 1 (US)

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (J...

View Details